FDA Clears IND Application of Tranzyme’s Gastric Drug
February 1, 2008
The FDA has accepted Tranzyme Pharma’s investigational new drug application for TZP-102 for the treatment of gastroparesis.
TZP-102 is a second generation prokinetic drug that Tranzyme intends to develop for the treatment of mild-to-moderate gastroparesis and other chronic gastrointestinal motility disorders. A Phase I safety and tolerability trial of TZP-102 will begin immediately.
Vipin Garg, president and CEO of Tranzyme, said: “Advancing TZP-102 into clinical development further strengthens our product pipeline. Acceptance of this IND by the FDA represents a significant milestone for Tranzyme as well as for the technology underlying the discovery and development of this product.”